The drug, vercirnon, relieved patients’ moderate-to-severe Chrohn’s symptoms no more than the placebo treatments. The study involved 608 patients who were given the treatment for three months.
Company executives expressed disappointment with the results, and GSK will revisit the drug’s development program.
More Articles on Gastroenterology:
Endoscopic Surveillance of Barrett’s Esophagus Not Linked With Cancer Survival
Bariatric Surgery Does Not Reduce Long Term Healthcare Costs, Study Says
EndoChoice’s Fuse System Cuts Down on Missed Colon Adenomas, Study Shows
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
